Abstract | CONTEXT: CASE PRESENTATION: A 55-year-old female was diagnosed with CD in 1973 at age 15 years and underwent bilateral adrenalectomy 1 year later. She subsequently developed Nelson's syndrome and underwent multiple surgeries and radiotherapy for adenoma growth. After presentation with ocular pain, third cranial nerve palsy, and a finding of suprasellar tumor enlargement with hemorrhage, she began pasireotide long-acting release 60 mg/28 days im. At baseline, fasting plasma ACTH was 42 710 pg/mL (normal, 5-27 pg/mL), and fasting plasma glucose was 98 mg/dL. After 1 month, ACTH declined to 4272 pg/mL, and it has remained stable over 19 months of follow-up. Hyperpigmentation progressively improved. Magnetic resonance imaging scans show reduction in the suprasellar component. Fasting plasma glucose increased to 124 mg/dL, and the patient underwent diabetes management. EVIDENCE ACQUISITION AND SYNTHESIS: In this clinical case seminar, the current understanding of the treatment of Nelson's syndrome and the use of pasireotide in CD are summarized. CONCLUSION: A case of Nelson's syndrome with clinically significant and dramatic biochemical and clinical responses to pasireotide administration is reported. Hyperglycemia was noted after pasireotide administration. Pasireotide may represent a useful tool in the medical management of Nelson's syndrome. Further study of the potential benefits and risks of pasireotide in this population is necessary.
|
Authors | Laurence Katznelson |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 98
Issue 5
Pg. 1803-7
(May 2013)
ISSN: 1945-7197 [Electronic] United States |
PMID | 23539733
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Delayed-Action Preparations
- Dipeptidyl-Peptidase IV Inhibitors
- Pyrazines
- Triazoles
- Somatostatin
- Adrenocorticotropic Hormone
- Growth Hormone-Releasing Hormone
- pasireotide
- Sitagliptin Phosphate
|
Topics |
- Adrenocorticotropic Hormone
(blood)
- Central Nervous System Cysts
(etiology, prevention & control)
- Delayed-Action Preparations
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Female
- Growth Hormone-Releasing Hormone
(antagonists & inhibitors)
- Humans
- Hyperglycemia
(chemically induced, drug therapy)
- Hyperpigmentation
(etiology, prevention & control)
- Middle Aged
- Nelson Syndrome
(blood, drug therapy, physiopathology)
- Pyrazines
(therapeutic use)
- Severity of Illness Index
- Sitagliptin Phosphate
- Somatostatin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Treatment Outcome
- Triazoles
(therapeutic use)
|